查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011319

新抗原標靶治療市場：按治療方法、治療途徑、給藥途徑、年齡層、標靶疾病和最終用戶分類 - 全球市場預測（2026-2032 年）

Neoantigen Targeted Therapies Market by Therapy Modality, Treatment Approach, Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，新抗原標靶治療市場價值將達到 53 億美元，到 2026 年將成長至 61.5 億美元，到 2032 年將達到 156.1 億美元，年複合成長率為 16.66%。

主要市場統計數據
基準年（2025 年） 53億美元
預計年份（2026年） 61.5億美元
預測年份（2032年） 156.1億美元
複合年成長率（） 16.66%

探索新抗原標靶治療前所未有的潛力，這可能會徹底改變全球個人化免疫腫瘤治療的模式。

標靶治療已成為腫瘤學研究的前沿領域，為癌症治療提供了高度個人化的方法。這些療法旨在利用腫瘤特異性突變，誘導強大的免疫反應，從而區分惡性細胞和正常細胞。這種模式轉移克服了傳統免疫療法的局限性，在降低脫靶毒性的同時，增強了針對每位患者的個人化抗腫瘤效果。

識別影響新抗原標靶治療在研究和臨床應用方面未來發展的關鍵變革性變化。

在生物技術進步和對腫瘤免疫學認知不斷加深的推動下，新抗原標標靶治療領域正經歷著翻天覆地的變革。近年來，前所未有的多學科專業知識融合，使得抗原發現流程得以快速完善，遞送平台得以最佳化。這種協同作用正在加速從研究到臨床應用的轉化，多個早期計畫已在固體癌和血液系統惡性腫瘤中展現出令人鼓舞的安全性和有效性。

評估美國提案的2025 年關稅對新抗原療法供應鏈和研究投資的累積影響。

美國政府提案對關鍵原料、試劑和成品生技藥品徵收關稅，這給新抗原療法的研發者帶來了一系列複雜的挑戰。許多供應鏈依賴受進口關稅影響的專用酵素、細胞培養基和一次性系統。隨著這些成本壓力不斷累積，研發預算面臨日益緊張的局面，這可能導致研發工作延誤，並延長臨床試驗所需時間。

透過多方面的市場區隔獲得的關鍵見解揭示了新抗原標靶治療及其應用案例中的機會。

市場區隔分析揭示了指南產品開發和商業化策略的關鍵差異化因素。根據治療方法類型，可分為兩大類：「過繼性細胞療法」和「個人化新抗原疫苗」。在過繼性細胞療法中，有不同的亞類，例如嵌合體抗原受體T細胞療法、基於T細胞受體的療法和腫瘤浸潤淋巴細胞療法，每種療法都面臨著獨特的生產挑戰和臨床應用前景。同時，疫苗平台包括基於樹突狀細胞的製劑、負載DNA或RNA的核酸構建體以及合成長肽製劑，每種製劑都採用不同的遞送系統和佐劑來最佳化免疫抗原性。

闡明美洲、歐洲、中東和非洲以及亞太地區新抗原療法擴展的趨勢和成長要素。

區域趨勢在新抗原標靶治療的引入和發展中發揮著至關重要的作用。在美洲，對生物技術中心、綜合醫療保健系統和患者支持網路的大力投資，為早期臨床試驗和商業化創造了肥沃的土壤。該地區的監管機構也展現出柔軟性，提供快速核准流程，促進了新型免疫療法的快速研發。

評估推動以新抗原為重點的癌症治療創新和商業化的領先生物製藥公司的策略趨勢。

領先的生物製藥公司正策略性地投資新抗原發現平台、生產規模化和臨床開發夥伴關係，以確保先發優勢。創新Start-Ups憑藉其專有的機器學習演算法預測可靠的新表位，從而脫穎而出；而大型企業則利用其生產經驗來簡化自體細胞製程流程。

為行業領導者制定切實可行的策略，以應對新抗原治療領域的新挑戰並抓住機會。

產業領導者應優先考慮將先進的分析技術整合到新抗原發現流程中。投資高通量表位篩檢和強大的生物資訊流程，能夠幫助企業提高候選藥物篩選的準確性，縮短研發週期，並最終降低臨床風險。將策略性資源配置到模組化生產平台，可以提高營運靈活性，並降低每批產品的資本支出。

概述了用於檢驗新抗原標標靶治療市場分析的數據和見解的穩健的多階段調查方法。

本分析的調查方法結合了全面的二手資料研究和有針對性的原始檢驗。首先，我們進行了廣泛的文獻綜述和專利趨勢評估，以確定關鍵的技術進步和智慧財產權趨勢。監管申報文件、臨床試驗註冊資訊和科學會議紀要構成了處於不同研發階段的治療藥物的基礎資料庫。

本研究整合了關鍵發現和意義，以突顯腫瘤治療中新抗原標標靶治療的未來發展。

精準免疫學、先進製造技術和數據驅動藥物發現的融合，使新抗原標靶治療成為癌症治療領域的突破性創新。分析表明，治療方法的多樣化、法規環境的演變以及策略聯盟正在加速臨床開發，並為更廣泛的商業化做好準備。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章 新抗原標靶治療市場：依治療方法分類

  • 過繼性細胞療法
    • CAR-T細胞療法
    • T細胞受體（TCR）療法
    • 腫瘤浸潤淋巴細胞（TILs）
  • 個人化新抗原疫苗
    • 樹突狀細胞（DC）疫苗
    • DNA/RNA疫苗
    • 胜肽（SLP）疫苗

第9章 新抗原標靶治療市場：依治療方法分類

  • 聯合治療
  • 單藥治療

第10章：新抗原標靶治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下

第11章 新抗原標靶治療市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第12章 新抗原標靶治療市場：以標靶疾病分類

  • 骨癌
  • 結腸癌
  • 婦科癌症
  • 非小細胞肺癌
  • 腎臟細胞癌

第13章 新抗原標靶治療市場：依最終用戶分類

  • 學術和政府附屬研究機構
  • 醫院和診所
  • 專科診所

第14章 新抗原標靶治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 新抗原標靶治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 新抗原標靶治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國新抗原標標靶治療市場

第18章：中國新抗原標標靶治療市場

第19章 競爭情勢

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • Achilles Therapeutics Limited
  • Agenus Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CureVac NV
  • Eli Lilly and Company
  • EpiVax, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genocea Biosciences, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Gritstone bio, Inc.
  • Immatics NV
  • Immunomic Therapeutics, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neon Therapeutics, Inc.
  • Nykode Therapeutics
  • Pfizer Inc.
  • Precision Biologics
  • Valo Therapeutics Ltd
Product Code: MRR-43078BB92C77

The Neoantigen Targeted Therapies Market was valued at USD 5.30 billion in 2025 and is projected to grow to USD 6.15 billion in 2026, with a CAGR of 16.66%, reaching USD 15.61 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.30 billion
Estimated Year [2026] USD 6.15 billion
Forecast Year [2032] USD 15.61 billion
CAGR (%) 16.66%

Exploring the Unprecedented Potential of Neoantigen Targeted Therapies to Revolutionize Personalized Immuno-Oncology Treatment Paradigms Worldwide

Neoantigen targeted therapies have emerged at the forefront of oncology research, offering highly personalized approaches to cancer treatment. By harnessing unique tumor-specific mutations, these therapies aim to stimulate robust immune responses that distinguish malignant cells from their healthy counterparts. This paradigm shift addresses the limitations of conventional immunotherapies, reducing off-target toxicity and enhancing antitumor efficacy on an individual patient basis.

Researchers and clinicians have dedicated significant efforts to unraveling the molecular underpinnings of neoantigen recognition, enabling the design of adoptive cell therapies and bespoke vaccine platforms. As a result, academic centers are collaborating closely with biopharmaceutical innovators, accelerating the translation of preclinical discoveries into early-phase clinical trials. This collaborative dynamic sets the stage for a new era of precision oncology, where treatment regimens are tailored to genomic signatures rather than histological classifications alone.

Moreover, advancements in computational algorithms and next-generation sequencing have streamlined neoantigen identification, reducing the time required to formulate patient-specific therapeutics. With increasing regulatory support and streamlined manufacturing processes, the field is poised for rapid expansion, offering the promise of durable responses and improved survival for patients with diverse tumor indications.

Furthermore, as the global healthcare ecosystem places greater emphasis on value-based care, the cost-effectiveness and scalability of neoantigen therapies are under rigorous evaluation. Stakeholders are assessing manufacturing workflows, quality control standards, and logistics to ensure that these bespoke treatments can be delivered at scale without compromising safety or efficacy.

Identifying the Key Transformative Shifts Shaping the Neoantigen Targeted Therapy Landscape Across Research and Clinical Application Domains

The landscape of neoantigen targeted therapies is undergoing seismic transformation driven by advances in biotechnology and a deeper understanding of tumor immunology. Recent years have witnessed an unprecedented convergence of multidisciplinary expertise, enabling the rapid refinement of antigen discovery pipelines and the optimization of delivery platforms. This synergy has accelerated the transition from bench to bedside, with multiple early-stage programs demonstrating encouraging safety and efficacy profiles in solid and hematologic malignancies.

In parallel, the integration of artificial intelligence and machine learning into epitope prediction and neoantigen prioritization has further elevated the field's potential. These computational tools facilitate high-throughput screening and enhance the precision of immunogenic candidate selection. Consequently, developers are exploring novel constructs that combine adoptive cell therapies with antigen-specific vaccination strategies to amplify T cell responses and overcome immunosuppressive microenvironments.

Manufacturing innovations are also reshaping the therapeutic ecosystem. Modular and automated production platforms are reducing batch variability and turnaround times, while quality-by-design principles are ensuring consistent product attributes. Regulatory agencies have responded by issuing guidance frameworks that support accelerated pathways and adaptive trial designs, reflecting a growing recognition of the unique nature of personalized immunotherapies.

Looking ahead, strategic partnerships between biotech innovators, contract development and manufacturing organizations, and healthcare providers will be critical. These alliances will drive economies of scale, improve access to specialized infrastructure, and enable the simultaneous exploration of novel combinations, further solidifying neoantigen targeted therapies as a cornerstone of future oncologic care.

Assessing the Cumulative Impact of Proposed United States Tariffs on Neoantigen Therapy Supply Chains and Research Investments in 2025

Proposed tariffs by the United States government on key raw materials, reagents, and finished biologics present a complex set of challenges for neoantigen therapy developers. Many supply chains rely on specialized enzymes, cell culture media, and single-use systems that are subject to import duties. As these cost pressures accumulate, research and development budgets face tighter constraints, potentially slowing investigative efforts and prolonging time to clinic.

In response, companies are reevaluating sourcing strategies and exploring domestic manufacturing alternatives. Some biopharma organizations have initiated feasibility studies to repatriate critical production steps, aiming to insulate their operations from fluctuating international trade policies. While this approach can mitigate tariff exposure, it often requires substantial capital investment in infrastructure, workforce training, and quality assurance protocols.

Moreover, delays at customs checkpoints and increased documentation requirements can disrupt just-in-time manufacturing models, leading to extended lead times and idle production capacity. This dynamic underscores the importance of supply chain resilience and risk diversification, particularly for therapies with compressed clinical timelines.

Despite these headwinds, there are opportunities for innovation. Companies that streamline their vendor portfolios, adopt regional stockpiling strategies, and leverage strategic alliances with contract manufacturers stand to reduce overhead and maintain timeline commitments. In a broader context, the tariff environment may incentivize policymakers and industry stakeholders to collaborate on trade agreements that recognize the critical value of advanced therapies, ultimately fostering a more predictable regulatory and economic landscape.

Deriving Key Insights from Multifaceted Market Segmentation to Illuminate Opportunities in Neoantigen Targeted Therapeutic Modalities and Use Cases

Market segmentation analysis reveals critical differentiators that inform product development and commercialization strategies. Based on therapy modality, two primary categories emerge: adoptive cell therapies and personalized neoantigen vaccines. Within adoptive cell therapies, distinct subcategories such as chimeric antigen receptor T cell therapy, T cell receptor-based therapy, and tumor-infiltrating lymphocyte approaches each present unique manufacturing challenges and clinical profiles. Meanwhile, vaccine platforms span dendritic cell-based preparations, nucleic acid constructs employing DNA or RNA payloads, and synthetic long peptide formulations, each leveraging different delivery and adjuvant systems to optimize immunogenicity.

Examining treatment approach sheds light on the evolving balance between monotherapy regimens and combination protocols. Combination approaches pairing neoantigen-directed modalities with checkpoint inhibitors or targeted agents are increasingly prevalent, aiming to amplify antitumor responses while counteracting immunosuppressive signals within the tumor microenvironment.

Route of administration further delineates product positioning. Oral formulations are under exploration for select vaccine candidates, but parenteral delivery remains the mainstay. Intramuscular injection is favored for dendritic cell vaccines, whereas intravenous infusion is required for most autologous cell therapies, and subcutaneous administration is being trialed to enhance patient compliance in select peptide-based interventions.

Age group segmentation underscores differential therapeutic considerations for adult, geriatric, and pediatric populations. Variable immune system maturity and comorbidity profiles drive tailored dosing and safety monitoring frameworks. Likewise, diverse target disease indications-from bone cancers and colorectal malignancies to gynecological tumors, non-small cell lung cancer, and renal cell carcinoma-demand bespoke neoantigen selection algorithms and clinical trial designs.

Finally, the end-user landscape spans academic and government research institutes spearheading early discovery, hospitals and clinics delivering clinical care, and specialty centers providing advanced immunotherapy infusion services. Understanding the unique needs and purchasing behaviors across these settings is essential for market entry and commercialization planning.

Uncovering Regional Dynamics and Growth Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific in Neoantigen Therapy Expansion

Regional dynamics play a pivotal role in shaping the adoption and development of neoantigen targeted therapies. In the Americas, robust investment in biotech hubs, integrated healthcare systems, and patient advocacy networks has created fertile ground for early-phase clinical trials and commercial launches. Regulatory bodies in this region have also demonstrated flexibility, offering expedited review pathways that facilitate rapid investigation of novel immunotherapies.

Conversely, the Europe, Middle East & Africa corridor presents a heterogeneous environment. Western European markets benefit from well-established reimbursement frameworks and centralized regulatory bodies, while emerging Middle Eastern and African countries are increasingly investing in advanced biomanufacturing infrastructure to address regional disease burdens. Collaborative consortia and cross-border trial networks are leveraging these developments to broaden patient access and diversify trial populations.

Across Asia-Pacific, government initiatives targeting biotech innovation, coupled with expanding healthcare coverage and a large patient pool, are driving significant momentum. Countries in this region are particularly focused on building local manufacturing capabilities and forging public-private partnerships to accelerate translational research. These efforts are complemented by tailored regulatory adaptations that address the unique logistical and cultural considerations inherent to personalized therapies.

Collectively, these regional insights underscore the importance of localized market entry strategies, adaptive pricing models, and strategic alliances with governmental and academic stakeholders. Companies that navigate these diverse dynamics effectively will be well positioned to capture value and drive global expansion.

Evaluating Strategic Movements of Leading Biopharma Players Driving Innovation and Commercialization in Neoantigen Focused Cancer Therapies

Leading biopharmaceutical companies are strategically investing in neoantigen discovery platforms, manufacturing scale-up, and clinical development partnerships to secure first-mover advantages. Innovative startups are differentiating through proprietary machine learning algorithms that predict high-confidence neoepitopes, while larger organizations are leveraging their manufacturing expertise to streamline autologous cell process workflows.

Several publicly traded entities have announced collaborations with academic centers to access patient biopsy repositories and accelerate biomarker validation. These alliances not only enhance candidate selection but also establish real-world evidence generation frameworks that support payer engagement discussions. Concurrently, contract development and manufacturing organizations are expanding cleanroom capacity and introducing modular production suites specifically tailored for personalized immunotherapies.

In the vaccine segment, companies with nucleic acid expertise are repurposing existing RNA platforms, adapting lipid nanoparticle formulations to accommodate neoantigen payloads, and optimizing cold chain logistics. This approach benefits from established supply networks and offers a rapid response capability for individualized therapy manufacturing.

Adoptive cell therapy pioneers are pursuing allogeneic "off-the-shelf" strategies to mitigate time-to-treatment challenges, while ensuring robust safety switches and T cell persistence mechanisms. Their efforts are complemented by ongoing investment in cell editing technologies to enhance target specificity and reduce cytokine release syndrome incidence. The combined focus on innovative modality development, scalable manufacturing, and comprehensive safety profiling is accelerating the emergence of commercially viable neoantigen products poised to transform oncology care.

Implementing Actionable Strategies for Industry Leaders to Navigate Emerging Challenges and Capitalize on Opportunities in Neoantigen Therapeutics

Industry leaders should prioritize the integration of advanced analytics into their neoantigen discovery workflows. By investing in high-throughput epitope screening and robust bioinformatic pipelines, organizations can improve candidate selectivity, reduce development cycles, and ultimately de-risk clinical outcomes. Strategic allocation of resources toward modular manufacturing platforms will enhance operational agility and reduce capital expenditure per product batch.

Fostering cross-sector collaborations is equally critical. Partnerships between biotech innovators, academic institutions, and contract manufacturers can unlock shared infrastructure, accelerate proof-of-concept studies, and facilitate rapid scale-up. Leaders should also engage with regulatory agencies early to align on adaptive trial designs and breakthrough designation opportunities, thereby ensuring that novel therapies reach patients without unnecessary delays.

To maximize commercial success, it is imperative to develop differentiated value propositions that address payer concerns around cost-effectiveness and real-world outcomes. Implementing longitudinal patient registries and health economics studies will support reimbursement negotiations and demonstrate long-term benefits over standard-of-care. Additionally, embracing flexible pricing models and risk-sharing agreements can alleviate financial barriers for healthcare providers.

Finally, executives must cultivate talent with dual expertise in immunology and bioprocess engineering. Building cross-functional teams capable of navigating both scientific and operational complexities will position organizations to respond swiftly to emerging data, optimize manufacturing protocols, and deliver personalized therapies at scale.

Outlining a Robust Multi-Phase Research Methodology to Validate Data and Insights Underpinning the Neoantigen Targeted Therapies Market Analysis

The research methodology underpinning this analysis combines comprehensive secondary research with targeted primary validation. Initially, extensive literature reviews and patent landscape assessments were conducted to identify key technological advancements and intellectual property trends. Regulatory filings, clinical trial registries, and scientific conference proceedings provided a foundational database of therapeutics in various stages of development.

Subsequently, in-depth interviews with senior executives, scientific directors, and manufacturing leads at companies active in neoantigen modalities enriched the dataset. These discussions focused on platform capabilities, pipeline prioritization, and strategic partnerships, offering nuanced perspectives that are not readily available in public domains. Additional insights were gathered through consultations with regulatory experts to clarify evolving approval pathways and policy initiatives.

Quantitative data collection included benchmarking of manufacturing costs, reagent sourcing challenges, and supply chain lead times across different geographic regions. This information was triangulated against proprietary databases and industry reports to ensure accuracy. Lastly, all findings were subjected to an internal peer review process, incorporating feedback from immuno-oncology specialists to validate technical content and refine analytical frameworks.

Synthesizing Key Findings and Implications to Highlight the Future Trajectory of Neoantigen Targeted Therapies in Oncology Care

The convergence of precision immunology, advanced manufacturing, and data-driven discovery has positioned neoantigen targeted therapies as a defining innovation in cancer treatment. This analysis highlights how modality diversification, regulatory evolution, and strategic collaborations are collectively accelerating clinical progress and preparing the market for broader commercialization.

While challenges such as supply chain resilience, tariff impacts, and reimbursement frameworks require careful management, the underlying scientific momentum and unmet medical need create a conducive environment for sustained growth. Companies that strategically invest in scalable infrastructure, prioritize robust candidate selection, and maintain adaptive trial designs will unlock new avenues for patient benefit.

Looking forward, the integration of combination regimens, expansion into underserved patient populations, and ongoing optimization of safety profiles will be pivotal. The ability to deliver personalized therapies with precise targeting and manageable manufacturing timelines will ultimately determine market leadership and therapeutic impact.

By synthesizing the key insights presented in this report, stakeholders can better navigate the complexities of neoantigen targeted therapy development and deployment. Armed with a clear understanding of segment-specific dynamics, regional nuances, and competitive landscapes, decision-makers are well positioned to drive the next wave of innovation in immuno-oncology treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neoantigen Targeted Therapies Market, by Therapy Modality

  • 8.1. Adoptive Cell Therapy
    • 8.1.1. CAR-T Cell Therapy
    • 8.1.2. T Cell Receptor (TCR) Therapy
    • 8.1.3. Tumor-infiltrating lymphocytes (TIL)
  • 8.2. Personalized Neoantigen Vaccines
    • 8.2.1. Dendritic Cell (DC) Vaccines
    • 8.2.2. DNA/ RNA-based Vaccines
    • 8.2.3. Peptide (SLP) Vaccines

9. Neoantigen Targeted Therapies Market, by Treatment Approach

  • 9.1. Combination Therapy
  • 9.2. Monotherapy

10. Neoantigen Targeted Therapies Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous

11. Neoantigen Targeted Therapies Market, by Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Neoantigen Targeted Therapies Market, by Target Disease Indication

  • 12.1. Bone Cancer
  • 12.2. Colorectal Cancer
  • 12.3. Gynecological Cancer
  • 12.4. Non-Small Cell Lung Cancer
  • 12.5. Renal Cell Carcinoma

13. Neoantigen Targeted Therapies Market, by End-User

  • 13.1. Academic & Government Research Institutes
  • 13.2. Hospitals & Clinics
  • 13.3. Specialty Clinics

14. Neoantigen Targeted Therapies Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Neoantigen Targeted Therapies Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Neoantigen Targeted Therapies Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Neoantigen Targeted Therapies Market

18. China Neoantigen Targeted Therapies Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Achilles Therapeutics Limited
  • 19.6. Agenus Inc.
  • 19.7. AstraZeneca plc
  • 19.8. BioNTech SE
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. CureVac N.V.
  • 19.11. Eli Lilly and Company
  • 19.12. EpiVax, Inc.
  • 19.13. F. Hoffmann-La Roche AG
  • 19.14. Genentech, Inc.
  • 19.15. Genocea Biosciences, Inc.
  • 19.16. Gilead Sciences, Inc.
  • 19.17. GlaxoSmithKline plc
  • 19.18. Gritstone bio, Inc.
  • 19.19. Immatics N.V.
  • 19.20. Immunomic Therapeutics, Inc.
  • 19.21. IOVANCE Biotherapeutics, Inc.
  • 19.22. Medigene AG
  • 19.23. Merck & Co., Inc.
  • 19.24. Moderna, Inc.
  • 19.25. Neon Therapeutics, Inc.
  • 19.26. Nykode Therapeutics
  • 19.27. Pfizer Inc.
  • 19.28. Precision Biologics
  • 19.29. Valo Therapeutics Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 185. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 186. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 215. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 216. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 226. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 228. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)